Zynerba Pharmaceuticals (NASDAQ:ZYNE) and Millendo Therapeutics (NASDAQ:MLND) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations.
Risk and Volatility
Zynerba Pharmaceuticals has a beta of 4.8, indicating that its share price is 380% more volatile than the SP 500. Comparatively, Millendo Therapeutics has a beta of 2.61, indicating that its share price is 161% more volatile than the SP 500.
This table compares Zynerba Pharmaceuticals and Millendo Therapeutics’ top-line revenue, earnings per share and valuation.
Millendo Therapeutics has higher revenue and earnings than Zynerba Pharmaceuticals. Zynerba Pharmaceuticals is trading at a lower price-to-earnings ratio than Millendo Therapeutics, indicating that it is currently the more affordable of the two stocks.
Insider Institutional Ownership
19.3% of Zynerba Pharmaceuticals shares are held by